Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E known ✓ | A5X5Y0 | 4/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 4/20 | 0.96 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 4/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 4/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.65 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.65 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 4/20 | 0.77 |
| ▸ | ACR | P10323 | 3/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NOS1 | P29475 | 2/20 | 0.58 |
| ▸ | NOS2 | P35228 | 2/20 | 0.58 |
| ▸ | FURIN | P09958 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099711 | 0.98 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5423613 | 0.79 | NOS3 (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4334877 | 0.77 | NOS3 (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4334880 | 0.77 | NOS3 (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10656959 | 0.77 | NOS3 (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5112456 | 0.77 | NOS3 (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10513756 | 0.76 | NOS3 (0.63) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6618176 | 0.76 | HTR3E (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6138149 | 0.75 | HTR3E (0.62) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4099965 | 0.75 | ADRA2A (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | HAWLEY RONALD C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6846828-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1444223-A1 | AMINOPYRIMIDINES AND -PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | SYNTEX (U.S.A.) LLC | 2003-07-31 | — | — | US | disclosed |
| WO-2003040131-A1 | AMINOPYRIMIDINES AND PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| US-4324801-A | ANTIPYRETICS, ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTICOAGULANTS, INHIBITORS OF PROSTAGLANDIN FORMATION | BANYU PHARMACEUTICAL CO. LTD. (JP) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | HTR3E 3491/4885HTR3B 3045/4885HTR3A 3518/4885 |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | HTR3E 3469/4885HTR3B 3133/4885HTR3A 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.